CELCUITY INC (NASDAQ:CELC) Stock Surges 70% in a Month Following Q3 Earnings Beat and Positive Clinical Data

Recent Performance

Shares of Celcuity Inc (NASDAQ:CELC) have shown a notable positive reaction following the release of its third-quarter 2025 financial results. The stock experienced a significant uptick in after-hours trading, a movement that often indicates investor sentiment regarding the newly disclosed information. This positive momentum is part of a broader trend for the company, which has seen its stock price appreciate substantially over the past month.

• After-Market Performance: +2.16%
• One-Month Performance: +70.20%
• Two-Week Performance: +15.07%
• One-Week Performance: +14.16%

Q3 2025 Earnings Versus Estimates

The clinical-stage biotechnology company reported its financial figures for the quarter ended September 30, 2025. As a company focused on development and without a commercialized product, investors and analysts primarily monitor its cash burn and how its losses compare to expectations. In this regard, Celcuity delivered a positive surprise on its bottom line.

• Reported Revenue: $0.0 million
• Analyst Revenue Estimate: $0.0 million
• Reported EPS (Non-GAAP): -$0.92
• Analyst EPS Estimate (Non-GAAP): -$1.03

Celcuity met the revenue expectation of zero, which is standard for a pre-revenue biotech firm. The key takeaway is the earnings per share figure, which came in significantly better than the consensus estimate. The company's loss of $0.92 per share was approximately 11% narrower than the anticipated loss of $1.03 per share. This smaller-than-expected loss suggests disciplined management of operating expenses during the quarter.

Corporate Developments and Clinical Progress

Beyond the financial numbers, the company's corporate update highlighted important clinical milestones. A primary focus was on the company's lead therapeutic candidate, gedatolisib, which is being developed for advanced breast cancer. Celcuity presented detailed efficacy and safety results from the PIK3CA wild-type cohort of its pivotal Phase 3 VIKTORIA-1 clinical trial. The presentation of late-breaking data at a major medical conference is a significant event for a clinical-stage company, as it provides the investment and scientific communities with a critical look at the potential viability of its drug candidate. Positive data from such presentations can be a major catalyst for the stock, which may be contributing to the recent positive price performance.

Forward-Looking Estimates

Looking ahead, analyst projections for the company's financial trajectory remain consistent with its clinical-stage status. The estimates for the upcoming quarter and full year reflect the expectation that Celcuity will continue to incur losses as it advances its clinical programs.

• Q4 2025 Estimated EPS (Non-GAAP): -$1.06
• Q4 2025 Estimated Revenue: $0.0 million
• Full-Year 2025 Estimated EPS (Non-GAAP): -$3.86
• Full-Year 2025 Estimated Revenue: $0.0 million

The press release did not provide a specific financial outlook from management for the next quarter or full year. Therefore, the market's reaction appears to be driven predominantly by the earnings beat and the positive clinical updates, rather than by any forward guidance that deviated from analyst expectations.

For a more detailed breakdown of historical earnings and future analyst estimates, you can review the data here.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. The information presented should not be interpreted as a recommendation to buy or sell any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.